Lupin announces closure of Inspection by U.S. FDA at its Nagpur Unit-1 Facility with No Observations

Global pharma major Lupin Limited (Lupin) today announced that the United States Food and Drug Administration (U.S. FDA) has completed a product specific PreApproval Inspection at its Unit-1 oral solid dosage manufacturing facility in Nagpur. The inspection was carried out from November 10 to November 14, 2025, and concluded with zero 483 observations.

Nilesh Gupta, Managing Director, Lupin said, "The successful outcome of the U.S. FDA inspection at our Nagpur Unit-1 facility exemplifies our commitment to uphold and maintain the highest standards of quality, compliance, and safety across our facilities. We remain dedicated to improving the lives of our patients globally."

Shares of Lupin Limited was last trading in BSE at Rs. 2055.10 as compared to the previous close of Rs. 2052.90. The total number of shares traded during the day was 18808 in over 2141 trades.

The stock hit an intraday high of Rs. 2068.60 and intraday low of 2036.45. The net turnover during the day was Rs. 38613162.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Pharmaceuticals InspectionClosure USFDA Nagpur Unit1 NoObservations